Form 4: United Therapeutics COO Sells Shares Under 10b5-1 Plan

United Therapeutics President and COO Michael Benkowitz exercised options and sold 14,625 shares of common stock as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), exercised 14,625 stock options at a price of $117.76 per share.
• Concurrently, he sold all 14,625 shares of common stock acquired from the option exercise.
• The sales were executed in multiple trades on January 20, 2026, at weighted average prices ranging from $456.8663 to $470.755.
• These transactions were conducted under a Rule 10b5-1 trading plan established on June 3, 2025.
• Following these transactions, the direct beneficial ownership of common stock is 2,648 shares, and indirect beneficial ownership of derivative securities (options) by Trust is 67,875.

Sentiment

Score: 5

Explanation: The transaction is neutral as it represents a pre-planned exercise of options and sale of shares by an executive, which is a common occurrence for liquidity and portfolio diversification. The Rule 10b5-1 plan mitigates any negative sentiment typically associated with insider sales.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, undisclosed information.
• The exercise price of the options ($117.76) is significantly lower than the sale prices (ranging from $456.8663 to $470.755), indicating a substantial gain for the insider.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Industry Context

This is a routine insider transaction for an executive at a publicly traded pharmaceutical or biotechnology company. Such transactions are common for executives managing their personal portfolios and exercising vested stock options, especially when executed under a Rule 10b5-1 plan to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders may observe a slight reduction in the direct equity stake of a key executive, though the pre-planned nature of the sale under a 10b5-1 plan generally mitigates concerns about management's confidence in the company's future.

Key Dates

Recommendation

This Form 4 filing details a pre-planned insider transaction (option exercise and subsequent sale) by a key executive. Such transactions, especially when executed under a Rule 10b5-1 plan, are generally considered routine for executive compensation and personal financial planning. They do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Executive Compensation, Share Sale, Michael Benkowitz